Search: WFRF:(Ayoun Alsoud Rami) >
Model-informed drug...
Model-informed drug discovery and development strategy for the rapid development of anti-tuberculosis drug combinations
-
- Van Wijk, Rob C, 1991- (author)
- Uppsala universitet,Institutionen för farmaceutisk biovetenskap
-
- Ayoun Alsoud, Rami (author)
- Uppsala universitet,Institutionen för farmaceutisk biovetenskap
-
- Lennernäs, Hans (author)
- Uppsala universitet,Institutionen för farmaci
-
show more...
-
- Simonsson, Ulrika S H, Professor (author)
- Uppsala universitet,Institutionen för farmaceutisk biovetenskap
-
show less...
-
(creator_code:org_t)
- 2020-03-31
- 2020
- English.
-
In: Applied Sciences. - : MDPI AG. - 1454-5101 .- 2076-3417. ; 10
- Related links:
-
https://doi.org/10.3...
-
show more...
-
https://uu.diva-port... (primary) (Raw object)
-
https://www.mdpi.com...
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
show less...
Abstract
Subject headings
Close
- The increasing emergence of drug-resistant tuberculosis requires new effective and safe drug regimens. However, drug discovery and development are challenging, lengthy and costly.The framework of model-informed drug discovery and development (MID3) is proposed to be applied throughout the preclinical to clinical phases to provide an informative prediction of drug exposure and efficacy in humans in order to select novel anti-tuberculosis drug combinations. The MID3 includes pharmacokinetic-pharmacodynamic and quantitative systems pharmacology models, machine learning and artificial intelligence, which integrates all the available knowledge related to disease and the compounds. A translational in vitro-in vivo link throughout modeling and simulation is crucial to optimize the selection of regimens with the highest probability of receiving approval from regulatory authorities. In vitro-in vivo correlation (IVIVC) and physiologically-based pharmacokinetic modeling provide powerful tools to predict pharmacokinetic drug-drug interactions based on preclinical information. Mechanistic or semi-mechanistic pharmacokinetic-pharmacodynamic models have been successfully applied to predict the clinical exposure-response profile for anti-tuberculosis drugs using preclinical data. Potential pharmacodynamic drug-drug interactions can be predicted from in vitro data through IVIVC and pharmacokinetic-pharmacodynamic modeling accounting for translational factors. It is essential for academic and industrial drug developers to collaborate across disciplines to realize the huge potential of MID3.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
Keyword
- tuberculosis
- MID3
- pharmacokinetics
- pharmacodynamics
- drug-drug interactions
- in vitro
- in vivo
- drug development
- Pharmacology
- Farmakologi
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database